Assembly Up After Promising Early Cut Data From HBV Infection Programs
- Assembly Biosciences Inc announced interim efficacy, safety, and pharmacokinetic (PK) results from a Phase 1b study of ABI-H3733 (3733) and a Phase 1a study of ABI-4334 (4334).
- For the Phase 1b trial of 3733, the dose selected for the first cohort was 50 mg.
- A dose of 100 mg has been selected for the third cohort, for which dosing is ongoing, with initial data anticipated in Q1 of 2023.
- In the 50 mg cohort, six of eight patients receiving 3733 achieved HBV DNA less than the lower limit of quantification within 21 days, with a mean decline in HBV DNA over the treatment period of approximately 3.1 logs.
- Data on HBV RNA declines were limited due to low baseline levels in predominantly e-antigen-negative patients.
- In the 25-mg cohort of five patients that have completed 28 days of treatment, the mean reduction in HBV DNA was approximately 1.9 logs.
- The Phase 1a trial for 4334 dosing has been completed for all eight subjects in the initial 30 mg single-dose cohort.
- A dose of 100 mg has been selected for the second single-dose cohort. Dosing for the second cohort is complete and initial data is anticipated in Q1 of 2023.
- No serious adverse events or significant laboratory abnormalities were observed in either study.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.